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Background
Over one quarter of individuals in Sweden report suffering
from allergic rhinitis (AR), placing a considerable burden
on both sufferers and society [1]. In clinical trials MP29-
02* (a novel intranasal formulation of azelastine hydro-
chloride (AZE) and fluticasone propionate (FP) in an
advanced delivery system) provided complete/near com-
plete symptom control in 1 of 6 moderate/severe seasonal
AR (SAR) patients [2] and complete relief in 7 of 10 mild/
moderate perennial AR (PAR) patients [3]. This study
aimed to assess the effectiveness of MP29-02* in routine
clinical practice.
Method
Results from Sweden (n=431) from a multinational,
multicentre, prospective, observational study in adults/
adolescents with moderate/severe AR for whom MP29-
02* was prescribed according to SPC are reported.
Patients had acute AR symptoms on Day 0. Intended
study duration was 14 days. Patients assessed symptom
severity using a visual analog score (VAS) from 0mm
(not at all bothersome) to 100mm (very bothersome), in
the AM prior to MP29-02* use, on Days 0, 1, 3, 7 and
last day. This was described for the whole population and
according to phenotype (i.e. SAR, PAR or SAR + PAR)
and severity (less severe: baseline VAS=50-74mm; more
severe: baseline VAS ≥75mm). Patients’ perceived level of
disease control (i.e. well-, partly- and un-controlled) was
assessed on Day 3.
Results
MP29-02* (1 spray/nostril bd; daily doses: AZE:548µg,
FP:200µg) reduced VAS score from 67.9mm at baseline
to 32.1mm by last visit, a shift of 36.1mm. Effectiveness
was consistent regardless of phenotype or disease
severity. Symptom burden reduced rapidly in the first
days of treatment. 27% of all patients felt their symp-
toms were ‘well controlled’ and 43% felt their symptoms
were ‘partly-controlled’ at Day 3. This perception of
‘well-controlled’ symptoms at Day 3 corresponded to an
optimal VAS cut-off in Sweden of 39mm. On average
patients treated with MP29-02* crossed this well-con-
trolled VAS cut-off by Day 7.
Conclusion
MP29-02* provides effective and rapid symptom control in
Swedish AR patients in a real-world setting irrespective of
disease phenotype or severity, with responder rates higher
than those observed in a clinical trial with moderate/severe
AR patients, supporting MP29-02*’s position as the drug
of choice for the treatment of AR.
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